These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 17355866)

  • 1. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.
    Seeliger MA; Nagar B; Frank F; Cao X; Henderson MN; Kuriyan J
    Structure; 2007 Mar; 15(3):299-311. PubMed ID: 17355866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
    Healy EF; Johnson S; Hauser CR; King PJ
    FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.
    Cowan-Jacob SW; Fendrich G; Manley PW; Jahnke W; Fabbro D; Liebetanz J; Meyer T
    Structure; 2005 Jun; 13(6):861-71. PubMed ID: 15939018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecular mechanics model for imatinib and imatinib:kinase binding.
    Aleksandrov A; Simonson T
    J Comput Chem; 2010 May; 31(7):1550-60. PubMed ID: 20020482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
    Seeliger MA; Ranjitkar P; Kasap C; Shan Y; Shaw DE; Shah NP; Kuriyan J; Maly DJ
    Cancer Res; 2009 Mar; 69(6):2384-92. PubMed ID: 19276351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.
    Lin YL; Roux B
    J Am Chem Soc; 2013 Oct; 135(39):14741-53. PubMed ID: 24001034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate (STI571)-induced cell edge translocation of kinase-active and kinase-defective Abelson kinase: requirements of myristoylation and src homology 3 domain.
    Fujita A; Shishido T; Yuan Y; Inamoto E; Narumiya S; Watanabe N
    Mol Pharmacol; 2009 Jan; 75(1):75-84. PubMed ID: 18835981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of binding energy activity of imatinib and Abl tyrosine kinase domain based on simple consideration for conformational change: An explanation for variation in imatinib effect in mutated type.
    Wiwanitkit V
    Indian J Cancer; 2009; 46(4):335-6. PubMed ID: 19749465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
    Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Src-like inactive conformation in the abl tyrosine kinase domain.
    Levinson NM; Kuchment O; Shen K; Young MA; Koldobskiy M; Karplus M; Cole PA; Kuriyan J
    PLoS Biol; 2006 May; 4(5):e144. PubMed ID: 16640460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R
    Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
    Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ
    ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation.
    Lovera S; Sutto L; Boubeva R; Scapozza L; Dölker N; Gervasio FL
    J Am Chem Soc; 2012 Feb; 134(5):2496-9. PubMed ID: 22280319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases.
    Aleksandrov A; Simonson T
    J Biol Chem; 2010 Apr; 285(18):13807-15. PubMed ID: 20200154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the c-Abl and Bcr-Abl tyrosine kinases.
    Hantschel O; Superti-Furga G
    Nat Rev Mol Cell Biol; 2004 Jan; 5(1):33-44. PubMed ID: 14708008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
    Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
    ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.
    Yang LJ; Zou J; Xie HZ; Li LL; Wei YQ; Yang SY
    PLoS One; 2009 Dec; 4(12):e8470. PubMed ID: 20041122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
    Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex.
    Jacobs MD; Caron PR; Hare BJ
    Proteins; 2008 Mar; 70(4):1451-60. PubMed ID: 17910071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.